295 related articles for article (PubMed ID: 19820010)
1. Glucagon-like peptide-1 receptor imaging for localization of insulinomas.
Christ E; Wild D; Forrer F; Brändle M; Sahli R; Clerici T; Gloor B; Martius F; Maecke H; Reubi JC
J Clin Endocrinol Metab; 2009 Nov; 94(11):4398-405. PubMed ID: 19820010
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 receptor imaging for the localisation of insulinomas: a prospective multicentre imaging study.
Christ E; Wild D; Ederer S; Béhé M; Nicolas G; Caplin ME; Brändle M; Clerici T; Fischli S; Stettler C; Ell PJ; Seufert J; Gloor B; Perren A; Reubi JC; Forrer F
Lancet Diabetes Endocrinol; 2013 Oct; 1(2):115-22. PubMed ID: 24622317
[TBL] [Abstract][Full Text] [Related]
3. [Lys40(Ahx-DTPA-111In)NH2]exendin-4, a very promising ligand for glucagon-like peptide-1 (GLP-1) receptor targeting.
Wild D; Béhé M; Wicki A; Storch D; Waser B; Gotthardt M; Keil B; Christofori G; Reubi JC; Mäcke HR
J Nucl Med; 2006 Dec; 47(12):2025-33. PubMed ID: 17138746
[TBL] [Abstract][Full Text] [Related]
4. Superior Diagnostic Performance of the GLP-1 Receptor Agonist [Lys
Senica K; Tomazic A; Skvarca A; Kolenc Peitl P; Mikolajczak R; Hubalewska-Dydejczyk A; Lezaic L
Mol Imaging Biol; 2020 Feb; 22(1):165-172. PubMed ID: 31098984
[TBL] [Abstract][Full Text] [Related]
5. Development of
Kimura H; Matsuda H; Ogawa Y; Fujimoto H; Toyoda K; Fujita N; Arimitsu K; Hamamatsu K; Yagi Y; Ono M; Inagaki N; Saji H
Bioorg Med Chem; 2017 Feb; 25(4):1406-1412. PubMed ID: 28089587
[TBL] [Abstract][Full Text] [Related]
6. [Lys40(Ahx-DTPA-111In)NH2]-Exendin-4 is a highly efficient radiotherapeutic for glucagon-like peptide-1 receptor-targeted therapy for insulinoma.
Wicki A; Wild D; Storch D; Seemayer C; Gotthardt M; Behe M; Kneifel S; Mihatsch MJ; Reubi JC; Mäcke HR; Christofori G
Clin Cancer Res; 2007 Jun; 13(12):3696-705. PubMed ID: 17575235
[TBL] [Abstract][Full Text] [Related]
7. Glucagon-Like Peptide-1 Receptor PET/CT with 68Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study.
Luo Y; Pan Q; Yao S; Yu M; Wu W; Xue H; Kiesewetter DO; Zhu Z; Li F; Zhao Y; Chen X
J Nucl Med; 2016 May; 57(5):715-20. PubMed ID: 26795291
[TBL] [Abstract][Full Text] [Related]
8. Comparison of glucagon-like peptide-1 receptor (GLP-1R) PET/CT, SPECT/CT and 3T MRI for the localisation of occult insulinomas: evaluation of diagnostic accuracy in a prospective crossover imaging study.
Antwi K; Fani M; Heye T; Nicolas G; Rottenburger C; Kaul F; Merkle E; Zech CJ; Boll D; Vogt DR; Gloor B; Christ E; Wild D
Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2318-2327. PubMed ID: 30054698
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like Peptide-1 Receptor as Emerging Target: Will It Make It to the Clinic?
Wild D; Antwi K; Fani M; Christ ER
J Nucl Med; 2021 Jul; 62(Suppl 2):44S-50S. PubMed ID: 34230073
[TBL] [Abstract][Full Text] [Related]
10. 18F-radiolabeled GLP-1 analog exendin-4 for PET/CT imaging of insulinoma in small animals.
Wu H; Liang S; Liu S; Pan Y; Cheng D; Zhang Y
Nucl Med Commun; 2013 Jul; 34(7):701-8. PubMed ID: 23652208
[TBL] [Abstract][Full Text] [Related]
11. Innovative imaging of insulinoma: the end of sampling? A review.
Christ E; Antwi K; Fani M; Wild D
Endocr Relat Cancer; 2020 Apr; 27(4):R79-R92. PubMed ID: 31951592
[TBL] [Abstract][Full Text] [Related]
12. Use of the incretin hormone glucagon-like peptide-1 (GLP-1) for the detection of insulinomas: initial experimental results.
Gotthardt M; Fischer M; Naeher I; Holz JB; Jungclas H; Fritsch HW; Béhé M; Göke B; Joseph K; Behr TM
Eur J Nucl Med Mol Imaging; 2002 May; 29(5):597-606. PubMed ID: 11976797
[TBL] [Abstract][Full Text] [Related]
13. Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.
Eriksson O; Velikyan I; Selvaraju RK; Kandeel F; Johansson L; Antoni G; Eriksson B; Sörensen J; Korsgren O
J Clin Endocrinol Metab; 2014 May; 99(5):1519-24. PubMed ID: 24512490
[TBL] [Abstract][Full Text] [Related]
14. 68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.
Brom M; Oyen WJ; Joosten L; Gotthardt M; Boerman OC
Eur J Nucl Med Mol Imaging; 2010 Jul; 37(7):1345-55. PubMed ID: 20111963
[TBL] [Abstract][Full Text] [Related]
15. Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Kaeppeli SAM; Jodal A; Gotthardt M; Schibli R; Béhé M
Mol Pharm; 2019 Sep; 16(9):3760-3769. PubMed ID: 31393738
[TBL] [Abstract][Full Text] [Related]
16. [(68)Ga-exendin-4 PET-CT for the localization of occult insulinomas: a prospective cohort study].
Luo YP; Pan QQ; Li F; Yu M; Xing XP; Zhang TP; Zhao YP
Zhonghua Wai Ke Za Zhi; 2018 Nov; 56(11):837-842. PubMed ID: 30392304
[No Abstract] [Full Text] [Related]
17. Insulinoma imaging with glucagon-like peptide-1 receptor targeting probe (18)F-FBEM-Cys (39)-exendin-4.
Xu Y; Pan D; Xu Q; Zhu C; Wang L; Chen F; Yang R; Luo S; Yang M
J Cancer Res Clin Oncol; 2014 Sep; 140(9):1479-88. PubMed ID: 24838847
[TBL] [Abstract][Full Text] [Related]
18. Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc/EDDA)NH2]-exendin-4 for the detection of insulinoma.
Sowa-Staszczak A; Pach D; Mikołajczak R; Mäcke H; Jabrocka-Hybel A; Stefańska A; Tomaszuk M; Janota B; Gilis-Januszewska A; Małecki M; Kamiński G; Kowalska A; Kulig J; Matyja A; Osuch C; Hubalewska-Dydejczyk A
Eur J Nucl Med Mol Imaging; 2013 Apr; 40(4):524-31. PubMed ID: 23224740
[TBL] [Abstract][Full Text] [Related]
19. Development of an
Iikuni S; Kamei I; Ohara T; Watanabe H; Ono M
Mol Pharm; 2022 Mar; 19(3):1019-1027. PubMed ID: 35138111
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]